Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe - Seite 3

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2019 sales of USD 9.7 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.

Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.

Sandoz Global Communications

Chris Lewis Sandoz Global Communications [phone] (mobile) [e-mail]

Michelle Bauman Sandoz Global Communications [phone] (mobile) [e-mail]

Novartis Media Relations
E-mail: [e-mail]

Antonio Ligi Novartis Global Communications [phone] [e-mail]	Eric Althoff Novartis US Communications [phone] [e-mail]

Novartis Investor Relations
Central investor relations line: [phone]
E-mail: [e-mail]

Central		North America
Samir Shah	[phone]	Sloan Simpson	[phone]
Thomas Hungerbuehler	[phone]
Isabella Zinck	[phone]